Linaprazan
Clinical data | |
---|---|
Other names | AZD-0865 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C21H26N4O2 |
Molar mass | 366.465 g·mol−1 |
Linaprazan is an experimental drug for the treatment of
potassium-competitive acid blocker (P-CAB).[1][2] Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.[3]
The drug was then licensed to Cinclus Pharma,[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.[4]
References
- PMID 30595950.
- ^ "Linaprazan". Inxight Drugs. National Center for Advancing Translational Sciences.
- ^ Tong A (4 March 2020). "Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes". endpts.com.
- ^ a b "Linaprazan glurate". Cinclus Pharma.